Brompheniramine / dihydrocodeine / phenylephrine Pregnancy and Breastfeeding Warnings

Brand names: Centussin DHC, EndaCof-DH, Poly-Tussin DHC

Brompheniramine / dihydrocodeine / phenylephrine Pregnancy Warnings

Brompheniramine/dihydrocodeine/phenylephrine has been assigned to pregnancy category C by the FDA. Animal studies have not been reported. There are no controlled data in human pregnancy. The Collaborative Perinatal Project monitored 65 first trimester exposures to brompheniramine. Malformations were reported in 10 infants, a statistically significant association. In another 6509 live births, 172 mothers were exposed to Dimetapp (brompheniramine, phenylephrine and phenylpropanolamine). Five infants were born with congenital abnormalities resulting in a somewhat higher frequency than normal. Brompheniramine/dihydrocodeine/phenylephrine is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.

See references

Brompheniramine / dihydrocodeine / phenylephrine Breastfeeding Warnings

There are no data on the excretion of brompheniramine or dihydrocodeine into human milk. Small amounts of phenylephrine are secreted in breast milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer